Vapotherm in brief
Vapotherm is an unlisted company in the Medical Devices industry, based in Exeter, New Hampshire, USA. It was founded in 1999. In the year to December 2023 it had sales of $69 M and a net loss of $58 M. It employs about 550 people.
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Vapotherm
Vapotherm Inc. Is a corporation based in Exeter, New Hampshire that was founded in 1999 as a medical device manufacturer after creating the first heated and humidified high flow therapy nasal cannula system.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Vapotherm timeline
- 1999
- 🏁· approximateFounded
- 2003
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- 🔔Initial public offering on NYSEFinal prospectus filed with the SEC on 15 November 2018; shares registered for exchange trading on 9 November 2018.
- 2020
- 💰Record revenue of $126 millionFY2020, the highest of the 6 years on record.
Events of Vapotherm from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Vapotherm
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 20 September 2024 (Form 8-K).
Market cap history
World rank over time
Rank in USA: #3,007 (Jan 2020) · #2,473 (Jan 2021) · #3,226 (Jan 2022) · #4,586 (Dec 2022) · #5,252 (Jul 2023)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -84.7%
- Operating margin
- -56.9%
- Return on equity
- —
- Liabilities / assets
- 171.3%
- Revenue growth
- +2.8%
- R&D / revenue
- 20.7%
- Revenue per employee
- $125 K
- Profit per employee
- $-106 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2023 | $69M | +2.8% | $-39M | $-58M | -84.7% |
| Dec 2022 | $67M | -41.0% | $-100M | $-113M | -169.6% |
| Dec 2021 | $113M | -9.9% | $-57M | $-60M | -52.8% |
| Dec 2020 | $126M | +161.4% | $-43M | $-52M | -41.0% |
| Dec 2019 | $48M | +13.5% | $-48M | $-51M | -106.2% |
| Dec 2018 | $42M | — | $-37M | $-42M | -100.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2023 | $-24M | $3M | $-27M | $-9.64 | — |
| Dec 2022 | $-80M | $12M | $-92M | $-33.89 | — |
| Dec 2021 | $-55M | $6M | $-61M | $-2.31 | — |
| Dec 2020 | $-39M | $10M | $-49M | $-2.16 | — |
| Dec 2019 | $-40M | $5M | $-44M | $-2.74 | — |
| Dec 2018 | $-40M | $5M | $-45M | $-14.65 | — |
Quarterly results
Latest quarter to Jun 2024: revenue $17M (+5.2% on a year earlier), net income $-14M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Sep 20, 20248-KCurrent reportAcquisition or disposal completed · Listing notice · Unregistered share sale · Change in control · Directors or officers changed · Bylaws amended · Other events
- Sep 19, 20248-KCurrent reportShareholder vote
- Aug 12, 202410-QQuarterly report · period to Jun 2024
- Aug 12, 20248-KCurrent reportResults of operations
- Jun 20, 20248-KCurrent reportMaterial agreement · New financial obligation · Directors or officers changed
- May 9, 202410-QQuarterly report · period to Mar 2024
- May 9, 20248-KCurrent reportResults of operations
- Apr 29, 202410-K/AAnnual report (amended) · period to Dec 2023
- Apr 1, 20248-KCurrent reportMaterial agreement · New financial obligation · Regulation FD disclosure
- Feb 27, 20248-KCurrent reportDirectors or officers changed
- Feb 22, 202410-KAnnual report · period to Dec 2023
- Feb 22, 20248-KCurrent reportResults of operations
Official filings of Vapotherm with the US Securities and Exchange Commission.
Annual results
- Revenue
- $69 M
- Operating income
- $-39 M
- Net income
- $-58 M
For year ending December-2023 · source: SEC filing
Balance sheet
- Total assets
- $78 M
- Total liabilities
- $133 M
- Total equity
- $-55 M
As of December-2023
Insider trading at Vapotherm#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | John LandrySVP & Chief Financial Officer | Disposal to the company | -45,511 | — | — | 0 | Form 4 |
| filed | Anthony L. ArnerichDirector | Disposal to the company | -9,179 | — | — | 0 | Form 4 |
| filed | Lance A. BerryDirector | Disposal to the company | -22,485 | $2.180 | $49 K | 0 | Form 4 |
| filed | Donald J. SpenceDirector | Disposal to the company | -9,696 | $2.180 | $21 K | 0 | Form 4 |
| filed | Joseph ArmyPresident and CEO, Director | Disposal to the company | -392,094 | — | — | 0 | Form 4 |
| filed | Dorota McKayVP, Controller and CAO | Disposal to the company | -4,625 | — | — | 0 | Form 4 |
| filed | Mary Beth MoynihanDirector | Disposal to the company | -8,352 | $2.180 | $18 K | 0 | Form 4 |
| filed | Lori Lynn KnowlesDirector | Disposal to the company | -7,862 | $2.180 | $17 K | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Vapotherm#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 8-for-1 split ; 14-for-1 split
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Vapotherm scorecard#
Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 4). Fiscal year 2023.
Valuationnot known
Growth1 of 6
Profitability0 of 4
Financial health1 of 3
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Vapotherm: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 69 | 67 | 113 | 126 | 48 | 42 | |
| Cost of revenue | 40 | 50 | 60 | 63 | 27 | 26 | |
| Gross profit | 28 | 17 | 53 | 63 | 21 | 17 | |
| Research and development | 14 | 21 | 18 | 17 | 13 | 8.8 | |
| Selling and marketing | 33 | 46 | 60 | 65 | 38 | 34 | |
| General and administrative | 19 | 28 | 31 | 24 | 18 | 11 | |
| Operating expenses | 67 | 118 | 110 | 106 | 69 | 54 | |
| Operating income | −39 | −100 | −57 | −43 | −48 | −37 | |
| Interest and finance income | 0.1 | 0.1 | 0.1 | 0.3 | 0.9 | 0.1 | |
| Interest expense and finance costs | 19 | 12 | 2.6 | 4.7 | 5.1 | 3.1 | |
| Other non-operating income (expense) | — | — | 0.0 | −8.5 | −3.0 | −5.2 | |
| Income before tax | −58 | −113 | −60 | −52 | −51 | −42 | |
| Income tax | 0.1 | 0.0 | −0.1 | 0 | −0.1 | 0 | |
| Net income including minority interests | −58 | −113 | −60 | −52 | −51 | −42 | |
| Net income attributable to shareholders | −58 | −113 | −60 | −52 | −51 | −42 | |
| Earnings per share, basic | -9.64 | -33.89r | -2.31 | -2.16 | -2.74 | -14.65 | |
| Earnings per share, diluted | -9.64 | -33.89r | -2.31 | -2.16 | -2.74 | -14.65 | |
| Shares, weighted average (basic) | 6.0 | 3.3r | 26 | — | — | — | |
| Shares, weighted average (diluted) | 6.0 | 3.3r | 26 | 24 | 19 | 2.9 | |
| Balance sheet | |||||||
| Cash and cash equivalents | 9.7 | 16 | 57 | 114 | 72 | 58 | |
| Receivables | 11 | 9.1 | 11 | 23 | 8.2 | 7.1 | |
| Inventory | 23 | 33 | 37 | 20 | 9.1 | 14 | |
| Other current assets | 3.1 | 2.1 | 5.2 | 5.0 | 4.1 | 2.7 | |
| Current assets | 46 | 60 | 110 | 162 | 93 | 82 | |
| Property, plant and equipment | 24 | 27 | 22 | 21 | 15 | 13 | |
| Right-of-use (leased) assets | 3.4 | 5.8 | 7.0 | 8.3 | — | — | |
| Goodwill | 0.6 | 0.5 | 15 | 16 | 0.6 | 0 | |
| Other intangible assets | 0 | 0 | 4.4 | 5.7 | 0.4 | 0 | |
| Total assets | 78 | 96 | 160 | 216 | 112 | 97 | |
| Accounts payable | 5.1 | 2.7 | 5.9 | 5.0 | 3.4r | 3.1 | |
| Current liabilities | 19 | 20 | 43 | 42 | 16 | 14 | |
| Lease liabilities (non-current) | 2.9 | 5.9 | 5.4 | 6.8 | — | — | |
| Total liabilities | 133 | 124 | 93 | 102 | 58 | 46 | |
| Retained earnings | −548 | −490 | −377 | −317 | −265 | −214 | |
| Shareholders' equity | −55 | −28 | 67 | 114 | 54 | 52 | |
| Total liabilities and equity | 78 | 96 | 160 | 216 | 112 | 97 | |
| Shares outstanding | 6.2 | 3.6r | 26 | 26 | 21 | 17 | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 5.0 | 5.2 | 5.6 | 4.8 | 3.1 | 2.2 | |
| Share-based compensation | 9.6 | 10 | 9.8 | 6.4 | 3.8 | 0.5 | |
| Cash from operating activities | −24 | −80 | −55 | −39 | −40 | −40 | |
| Capital expenditure | −3.0 | −12 | −5.9 | −9.8 | −4.7 | −5.2 | |
| Acquisitions, net of cash acquired | — | — | −1.3 | −8.4 | −1.6 | — | |
| Cash from investing activities | −3.0 | −12 | −7.2 | −18 | −6.3 | −5.2 | |
| Debt issued | — | 99 | — | 40 | 11 | 32 | |
| Debt repaid | — | −40 | — | −43 | — | −22 | |
| Shares issued | — | 1.1 | — | 94 | 49 | 60 | |
| Cash from financing activities | 21 | 51 | 4.4 | 100 | 59 | 77 | |
| Exchange-rate effect on cash | — | — | — | — | 0.0 | — | |
| Change in cash | −6.0 | −40 | −58 | 42 | 13 | 32 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Vapotherm#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 5 · Restructuring 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 6 · New debt 5 · Unregistered share sale 2 · Shareholder rights changed 2 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Material agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Delisting noticeMaterial agreementNew debt | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K/A |
Source: SEC EDGAR, Form 8-K item numbers · as of Sep 20, 2024
Acquisitions and funding#
6 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2018 | $10 M | No. 6 | $10 to $50 million | 7 | equity | SEC |
| May 2017 | $20 M | No. 5 | $10 to $50 million | 15 | equity | SEC |
| Oct 2015 | $15 M | No. 4 | $10 to $50 million | 20 | equity | SEC |
| Mar 2015 | $20 M | No. 3 | $10 to $50 million | 19 | equity | SEC |
| Feb 2014 | $24 M | No. 2 | $10 to $50 million | 17 | equity | SEC |
| Mar 2013 | $26 M | No. 1 | $10 to $50 million | 10 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its annual reports since 2010, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Vapotherm#
3 labor condition applications certified in fiscal 2026 for 3 positions, at a median wage of $153 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Reliability EngineerBioengineers and Biomedical Engineers | 1 | $85 K |
| Senior Security Operations & Compliance EngineerInformation Security Engineers | 1 | $153 K |
| Sr. Quality DirectorIndustrial Production Managers | 1 | $197 K |
Where: Mesquite, TX 1 · Roanoke, VA 1 · Burlington, MA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 3 | 3 | $153 K | 3 |
| FY2024 | 2 | 2 | $120 K | 2 |
| FY2023 | 2 | 2 | $158 K | 2 |
| FY2020 | 2 | 2 | $92 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as VAPOTHERM, INC.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Vapotherm compares in Medical Devices
- Revenue$69 M · higher than 32% of 155
- Net margin-84.7% · higher than 17% of 144
- Revenue growth2.8% · higher than 26% of 104
- 🇺🇸 Eargo, Inc.$69 M
- 🇺🇸 ViewRay$70 M
- 🇳🇴 Medistim ASA$67 M
- 🇺🇸 Sientra, Inc.$71 M
- 🇺🇸 Misonix$62 M
- 🇸🇪 CellaVision AB (publ)$77 M
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Vapotherm🇺🇸 | $17 M | — | -84.7% | +2.8% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Abbott Laboratories$181.1 B
- Medtronic plc$121.2 B
- Stryker Corporation$116.5 B
- Boston Scientific Corporation$66.2 B
- Edwards Lifesciences Corporation$52.8 B
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.$27.8 B
Sources and freshness
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2023
- Balance sheet:
- As of December-2023
- Employees:
- As on 2021
- Profile updated:
- Nov 14, 2026
Figures from SEC filing, value.today research, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Vapotherm? Verify and update this profile — free
Show Vapotherm's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.